Treatment of vestibular disease is usually multimodal and includes treating underlying disease, when present, and providing supportive care for emesis and nausea. Drugs currently approved in veterinary medicine for management of nausea and vomiting include metoclopramide (a dopamine D2 receptor antagonist) and maropitant (a neurokinin-1 receptor antagonist). Both of these drugs can manage vomiting but lack antinausea properties when compared with placebo.1,2
Ondansetron (a 5-HT3 receptor antagonist) can eliminate nausea and vomiting in dogs2,3 and alleviates signs of kinetosis (ie, motion sickness), presumably due to the high distribution rate of 5-HT3 receptors in the area postrema.4,5 The area postrema lacks a specific blood–brain diffusion barrier to large polar molecules, and its specialized cells are therefore able to detect emetic toxins in the blood and CSF. Along with the nucleus of the solitary tract, this area is responsible for generating nausea and emesis.6
Nausea is a multidimensional sensation affected by vestibular inputs and other factors (eg, GI stimulation, physical and psychological factors)7 and is easier to quantify in humans, as they can report its existence and severity. Behavior and facial expressions are used in dogs and cats to evaluate the level of nausea, making it harder to quantify.
This study evaluated ondansetron as an antinausea drug in 16 dogs with nausea due to vestibular disease; only 31.3% of the dogs also had emesis. The intensity of nausea-like behavior (ie, salivation, lip licking, restlessness, lethargy, vocalization) was evaluated using a severity numeric scale prior to ondansetron administration (0.5 mg/kg IV) and 2 hours posttreatment. The occurrence and frequency of salivation, lip licking, restlessness, lethargy, and vomiting were significantly decreased in 11 dogs after ondansetron administration. The level of vocalization did not change.